CYGENE LABORATORIES NAMES ROBERT G. PINCO TO ADVISORY COUNCIL

ARCHIVED 2002–2016: Originally distributed via the eWire press wire service. Preserved as historical record.

CYGENE LABORATORIES NAMES ROBERT G. PINCO

SUBSCRIBE/UNSUBSCRIBE |

Corporate Responsibility

Science & Technology

Syndication Partners

**************************************************************************

E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE

**************************************************************************

CYGENE LABORATORIES NAMES ROBERT G. PINCO

CORAL SPRINGS, FLORIDA, Jan. 13 -/E-Wire/-- CyGene Laboratories, Inc. (OTC BB: CYGE.OB) announced today that Robert G. Pinco has joined the company's advisory council. Mr. Pinco is co-chairman of the BioMedical/FDA Practice and head of the firm's biotechnology group practice of Buchanan Ingersoll, a leading international law firm with specialization in the biotechnology sector. As a member of CyGene's advisory council Mr. Pinco will counsel its management team on matters pertaining to government regulatory approval for many of CyGene's new products and applications.

Based in Washington, D.C., Mr. Pinco has more than 25 years of experience in the pharmaceutical sector. As a former director of the Over-the-Counter Drug Review of the FDA, he directed a massive review of more than 400,000 nonprescription drugs, the largest, most complex project ever undertaken by that agency. He also held positions as former Associate White House Counsel, with the Drug Enforcement Administration (DEA), the U.S. Attorney's Office and as a pharmacist.

"Bob Pinco's expertise in effectively navigating new products through the Federal regulatory clearance and Buchanan Ingersoll's vast resources in the biotechnology sector are invaluable to CyGene as we prepare to introduce new products to the US marketplace," said Martin Munzer, chief executive officer of CyGene. "Bob's role on our advisory council will play an important role in CyGene's future growth."

About CyGene Laboratories, Inc. CyGene Laboratories, Inc., based in Coral Springs, Florida, is a development stage biotechnology company, which has developed a series of products with potential in biotechnology application development. The company creates proprietary genetic profiling and diagnostic testing methods with potential use for the medical marketplace. Since 1995 CyGene has been developing proprietary and automated DNA and RNA testing systems which may be useful for the screening, monitoring and diagnosis of human, veterinary and plant diseases. CyGene's proprietary Haystack Processing' platform supports the highest possible levels of sensitivity and specificity available in the field of molecular diagnostics today. The company has also developed AGENDA', a proprietary automated genomic analysis platform. Visit www.cygenelabs.com.

Forward-Looking Statements The statements made in this press release discussing the potential of CyGene's products and the potential for regulatory approval are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, CyGene's raising sufficient funds to support its development, marketing efforts and corporate overhead, its ability to attract technical employees, the ability of CyGene's management to grow its business with limited assistance and its ability to meet a variety of regulatory requirements.. CyGene Laboratories has no duty and undertakes no obligation to update such statements.

CyGene Laboratories, Inc.

(954) 741-7077, ext. 4403

CyGene Laboratories, Inc.

http://www.cygenelabs.com

**************************************************************************

To Transmit Your News Over E-Wire, visit http://www.ewire.com or

call 1-[REDACTED-PHONE]. E-Wire Is Broadcast To Millions Of Readers Worldwide

**************************************************************************